Connect with us

Hi, what are you looking for?

Digital Health

Medtronic Inks Value-Based Care Pact with Spectrum Health

Medtronic has partnered with integrated Michigan health system Spectrum Health to create value-based healthcare programs, with an initial focus on automating identification of readmission events in patients who use a Medtronic cardiac resynchronization therapy device.

Medtronic Inks Value-Based Care Pact with Spectrum Health

Dive Brief:

  • Medtronic has partnered with integrated Michigan health system Spectrum Health to create value-based healthcare programs, with an initial focus on automating identification of readmission events in patients who use a Medtronic cardiac resynchronization therapy device.
  • This latest deal is risk based, according to Spectrum spokesperson Tim Hawkins, wherein the medtech giant agrees to pay the system if certain patient outcomes are not met. The partners are framing the collaboration as a chance to “use data and near real-time analytics to design programs intended to help standardize care, reduce clinical variation and deliver greater personalization of care.”
  • Medtronic has previously entered into value-based agreements with groups including Aetna and UnitedHealthcare, primarily in the diabetes space.

Dive Insight:

The move from volume to value in healthcare has increased interest in alternative payment models. In some cases, device manufacturers are taking on risk, as Medtronic did when it agreed to cover certain costs associated with the failure of its Tyrx antibacterial sleeves. Other deals, such as the Medtronic-Aetna partnership, give medtech companies a share of any costs saved or revenues made through the use of their products.

The first Medtronic-Spectrum program covers cardiac resynchronization therapy. Under an “existing financial accountability program,” the partners will automate identification of readmission events in people who use Medtronic pacemakers and defibrillators and its AdaptivCRT pacing algorithm. AdaptivCRT reduced 30-day readmissions in a clinical trial. Automating the identification of readmissions could enable Medtronic and Spectrum to see if the algorithm delivers that benefit in the real world.

That program alone may not have a significant impact on Medtronic. Spectrum has 14 hospitals and a health plan with 1 million members. However, there is scope for Medtronic and Spectrum to initiate further value-based programs and the collaboration could form part of a wider increase in the use of alternative payment models in the coming years.

The Trump administration set the stage for more value-based arrangements late last year by revising the Stark Law and Anti-Kickback Statute. The revisions, which took effect the day before President Biden was inaugurated, support reimbursement of bundles based on clinical outcomes and allow manufacturers to use two safe harbors to enter into arrangements for digital health technologies.

Seen on MedTech Dive: Article Link

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

Exclusives

IoT is transforming healthcare through wearables, SaMD, and AI. MedTech needs strong branding for the efficiency and cost savings this will provide.

Digital Health

The lack of standardization is a huge problem in the diagnosis and tracking of neurological disorders: because they are so complex and often slow...

FDA

System creates 3D models of the heart with unprecedented anatomical details, allowing physicians to better plan and personalize therapeutic interventions

FDA

Linear Health Sciences has received U.S. FDA clearance and Health Canada approval of its Orchid SRV, a tension-activated breakaway safety release valve designed to reduce the...

You May Also Like

Exclusives

Plug “digital healthcare solutions” into Google, and the results are clear: digital tools have taken the healthcare industry by storm. Innovators across the HealthTech...

Exclusives

PRIA clients are provided a high-touch, white-glove service to support their patient access services.

Exclusives

In Delray Beach, Florida, an emerging biopharma company, Cyrano Therapeutics, is planning a clinical trial using approved theophylline via a new intranasal pathway of...

Exclusives

The sky’s the limit for HealthTech PR and looking past traditional strategies to nontraditional avenues for engagement will allow agencies to stand out.